Are Pot Stocks Like Aurora Cannabis (TSX:ACB) and Hexo (TSX:HEXO) Running Out of Cash?

Aurora Cannabis and Hexo will have to infuse capital by the end of 2020 to keep operations going.

| More on:
Marijuana plant and cannabis oil bottles isolated

Image source: Getty Images

We know that cannabis companies have been struggling with structural and regulatory issues for a while. Most pot companies have reported less-than-impressive quarterly results over the last year, resulting in an extended bear run for investors.

The recreational marijuana industry has been rattled by illegal sales that still account for 40% of total Canadian cannabis sales. The slower-than-expected roll-out of retail stores in major provinces have resulted in high inventory levels.

Further, high capital expenditures and related investments have meant that pot companies are struggling to stay afloat and might very well run out of cash. According to a report from boutique investment bank Ello Capital, several cannabis companies, including heavyweights such as Aurora Cannabis (TSX:ACB)(NYSE:ACB) and Hexo (TSX:HEXO)(NYSE:HEXO), would need to raise additional capital sooner rather than later.

Several pot stocks are still reporting a negative EBITDA and operating cash flow. This suggests it will be difficult for companies to raise debt, forcing them to raise additional equity capital and resulting in the dilution of existing shareholder capital.

Aurora Cannabis

According to Ello Capital, Aurora Cannabis has about 2.3 months of leeway left before its cash balance is down to zero. Aurora ended the December quarter with a cash balance of $182.5 million. It has a total debt of $602 million, while its operating cash flow stands at -$288.9 million and free cash flow is at -$695 million.

Aurora Cannabis is grappling with several other issues. It announced the exit of founder and CEO Terry Booth recently. The company also had to stop construction for two key projects and announced close to $1 billion in balance sheet write-offs.

Aurora Cannabis stock has been pummeled in the last year. The stock is trading 84% below its 52-week high, and now with liquidity concerns, there is a chance that investors will continue to bleed in 2020 as well.

The massive correction for Aurora Cannabis has meant the stock is trading at a price-to-book ratio of 0.66. With a market cap of $2.55 billion, it is valued at 8.35 times forward sales.

Hexo is down 83% from 52-week high

Hexo is another company under the scanner. Ello Capital estimated Hexo’s cash balance to be enough for 6.5 months. Hexo already has raised about $100 million since October last year by equity offerings as well as convertible debentures.

Hexo ended the October quarter with a cash balance of $65.4 million. It has a total debt of $55 million, while its operating cash flow stands at -$138 million and free cash flow at -$246 million.

Hexo stock too has burnt investor wealth. The stock is currently trading 83% below its 52-week high. Shares fell 20% in January 2020 after Hexo’s acquisition of Newstrike came under the scanner. Newstrike was reportedly growing cannabis products illegally at its Beamsville facility in Niagara.

In fiscal 2020, Hexo aims to reduce operating expenses by 25%. Like most pot companies, Hexo is also banking on Cannabis 2.0 to drive product demand higher. Its partnership with Molson Coors can also help Hexo to stay afloat, which will give the firm a chance to make a comeback.

The verdict

There is a chance that Aurora, Hexo, and others may be able to issue additional capital in the upcoming months. However, there is also a chance that these companies will crash and burn considering the current pessimism surrounding pot stocks.

The cannabis industry is still at a nascent stage and can be likened to the dot com bubble of 2000. While Amazon and Alphabets’s Google rose from the ashes to generate millions of dollars in returns, there were hundreds of internet stocks that were wiped out without a trace.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool’s board of directors. David Gardner owns shares of Alphabet (A shares), Alphabet (C shares), and Amazon. Tom Gardner owns shares of Alphabet (A shares) and Alphabet (C shares). The Motley Fool owns shares of and recommends Alphabet (A shares), Alphabet (C shares), and Amazon. The Motley Fool recommends HEXO. and HEXO. Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »